Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
2.0
Journals
Children
Special Issues
Cardio-Oncology in Children
share announcement

Cardio-Oncology in Children

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Hematology & Oncology".

Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 15846

Special Issue Editors

Dr. Vasu D. Gooty

E-Mail Website
Guest Editor
Division of Pediatric Cardiology, University of Tennessee Health Science Center, LeBonheur Children’s Hospital, 49N Dunlap Street, FOB Room - 358Memphis, TN 38015, USA
Interests: pediatric cardiology; pediatric echocardiography; cardiac MRI and cTA; pediatric cardio-oncology; machine learning and artificial intelligence; multisystem inflammatory syndrome in children—MIS-C
Prof. Dr. Jeffrey A. Towbin

E-Mail Website
Guest Editor
Division of Pediatric Cardiology, Department of Pediatrics, LeBonheur Children’s Hospital, University of Tennessee, Memphis, TN 38104, USA
Interests: diagnostic and therapeutic advances for cardiomyopathies; heart failure and heart transplantation; cardiovascular genetics; cardio-oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is with great pleasure that we invite you to collaborate and contribute to this Special Issue on “Cardio-Oncology in Children”. With rapid advancement in the treatment of pediatric cancer, the overall mortality from cancer has been drastically reduced. However, there is increased recognition of cardiovascular toxicity secondary to standard and new cancer therapeutic agents that leads to heart failure and associated complications. The incidence and prevalence of cardiotoxicity is seen as early as during the initial stages of therapy and as late as years after completing therapy, a group known as long-term survivors of childhood cancers. This can lead to significant morbidity and mortality from cardiovascular complications. Several surveillance and treatment guidelines for the management of these patients have been published in the last 5–10 years; however, most of this literature is based on expert opinion, observational studies in children and limited robust clinical trials.

In this Special Issue, we envision providing a broad perspective in the field of pediatric cardio-oncology and hope to shed light on critical unanswered questions surrounding the cardiovascular care of children with cancer with topics ranging from pathophysiology to the management of these children and future trends and goals. We invite authors to submit a topic-based manuscript that provides readers with an overview of the current state and future of pediatric cardio-oncology. Please consider participating.

We look forward to hearing from you regarding your potential contribution.

Dr. Vasu D. Gooty
Prof. Dr. Jeffrey A. Towbin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardio-oncology
  • heart failure
  • cancer
  • cardiomyopathy
  • cardiotoxicity
  • chemotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 325 KiB  
Review
Current State of Pediatric Cardio-Oncology: A Review
by Molly Brickler, Alexander Raskin and Thomas D. Ryan
Children 2022, 9(2), 127; https://doi.org/10.3390/children9020127 - 19 Jan 2022
Cited by 5 | Viewed by 4906
Abstract
The landscape of pediatric oncology has dramatically changed over the course of the past several decades with five-year survival rates surpassing 80%. Anthracycline therapy has been the cornerstone of many chemotherapy regimens for pediatric patients since its introduction in the 1960s, and recent [...] Read more.
The landscape of pediatric oncology has dramatically changed over the course of the past several decades with five-year survival rates surpassing 80%. Anthracycline therapy has been the cornerstone of many chemotherapy regimens for pediatric patients since its introduction in the 1960s, and recent improved survival has been in large part due to advancements in chemotherapy, refinement of supportive care treatments, and development of novel therapeutics such as small molecule inhibitors, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors. Unfortunately, many cancer-targeted therapies can lead to acute and chronic cardiovascular pathologies. The range of cardiotoxicity can vary but includes symptomatic or asymptotic heart failure, arrhythmias, coronary artery disease, valvar disease, pericardial disease, hypertension, and peripheral vascular disease. There is lack of data guiding primary prevention and treatment strategies in the pediatric population, which leads to substantial practice variability. Several important future research directions have been identified, including as they relate to cardiac disease, prevention strategies, management of cardiovascular risk factors, risk prediction, early detection, and the role of genetic susceptibility in development of cardiotoxicity. Continued collaborative research will be key in advancing the field. The ideal model for pediatric cardio-oncology is a proactive partnership between pediatric cardiologists and oncologists in order to better understand, treat, and ideally prevent cardiac disease in pediatric oncology patients. Full article
(This article belongs to the Special Issue Cardio-Oncology in Children)
20 pages, 13639 KiB  
Review
Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care
by Hugo R. Martinez, Gary S. Beasley, Jason F. Goldberg, Mohammed Absi, Kaitlin A. Ryan, Karine Guerrier, Vijaya M. Joshi, Jason N. Johnson, Cara E. Morin, Caitlin Hurley, Ronald Ray Morrison, Parul Rai, Jane S. Hankins, Michael W. Bishop, Brandon M. Triplett, Matthew J. Ehrhardt, Ching-Hon Pui, Hiroto Inaba and Jeffrey A. Towbin
Children 2021, 8(12), 1200; https://doi.org/10.3390/children8121200 - 18 Dec 2021
Cited by 5 | Viewed by 4211
Abstract
Survival for pediatric patients diagnosed with cancer has improved significantly. This achievement has been made possible due to new treatment modalities and the incorporation of a systematic multidisciplinary approach for supportive care. Understanding the distinctive cardiovascular characteristics of children undergoing cancer therapies has [...] Read more.
Survival for pediatric patients diagnosed with cancer has improved significantly. This achievement has been made possible due to new treatment modalities and the incorporation of a systematic multidisciplinary approach for supportive care. Understanding the distinctive cardiovascular characteristics of children undergoing cancer therapies has set the underpinnings to provide comprehensive care before, during, and after the management of cancer. Nonetheless, we acknowledge the challenge to understand the rapid expansion of oncology disciplines. The limited guidelines in pediatric cardio-oncology have motivated us to develop risk-stratification systems to institute surveillance and therapeutic support for this patient population. Here, we describe a collaborative approach to provide wide-ranging cardiovascular care to children and young adults with oncology diseases. Promoting collaboration in pediatric cardio-oncology medicine will ultimately provide excellent quality of care for future generations of patients. Full article
(This article belongs to the Special Issue Cardio-Oncology in Children)
►▼ Show Figures

Figure 1

12 pages, 1099 KiB  
Review
Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
by Hari P. Tunuguntla, Kriti Puri and Susan W. Denfield
Children 2021, 8(10), 872; https://doi.org/10.3390/children8100872 - 30 Sep 2021
Viewed by 2423
Abstract
The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, [...] Read more.
The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction as a result of exposure to chemotherapy and/or radiation. Anthracyclines remain the most common cause of chemotherapy-induced cardiomyopathy (CCM) with varying clinical presentations including: acute, early onset, and late-onset. Many individuals develop cardiac dysfunction over the long-term, ranging from subclinical cardiac dysfunction to end-stage symptomatic heart failure. The focus of this review is on characterization of symptomatic heart failure in children with cancer therapy-related cardiac dysfunction (CTRCD) primarily due to CCM and utilization of advanced heart failure therapies, including ventricular assist device (VAD) support and heart transplantation, with consideration of unique patient-related factors. Full article
(This article belongs to the Special Issue Cardio-Oncology in Children)
►▼ Show Figures

Figure 1

14 pages, 972 KiB  
Review
Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy
by Claire Fraley, Sarah A. Milgrom, Lavanya Kondapalli, Matthew R. G. Taylor, Luisa Mestroni and Shelley D. Miyamoto
Children 2021, 8(9), 829; https://doi.org/10.3390/children8090829 - 21 Sep 2021
Cited by 2 | Viewed by 2734
Abstract
Cardiotoxicity is a well-recognized late effect among childhood cancer survivors. With various pediatric cancers becoming increasingly curable, it is imperative to understand the disease burdens that survivors may face in the future. In order to prevent or mitigate cardiovascular complications, we must first [...] Read more.
Cardiotoxicity is a well-recognized late effect among childhood cancer survivors. With various pediatric cancers becoming increasingly curable, it is imperative to understand the disease burdens that survivors may face in the future. In order to prevent or mitigate cardiovascular complications, we must first understand the mechanistic underpinnings. This review will examine the underlying mechanisms of cardiotoxicity that arise from traditional antineoplastic chemotherapies, radiation therapy, hematopoietic stem cell transplantation, as well as newer cellular therapies and targeted cancer therapies. We will then propose areas for prevention, primarily drawing from the anthracycline-induced cardiotoxicity literature. Finally, we will explore the role of human induced pluripotent stem cell cardiomyocytes and genetics in advancing the field of cardio-oncology. Full article
(This article belongs to the Special Issue Cardio-Oncology in Children)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop